1
|
Marzucco A, Gatti G, Montanari MS, Fantini M, Colosimo C, Tamburini MV, Arfilli V, Morotti M, Schiavone P, Congestrì F, Manera M, Denicolò A, Brandolini M, Taddei F, Grumiro L, Zannoli S, Dirani G, De Pascali AM, Sambri V, Cricca M. Evaluation of Biofilm Production and Antifungal Susceptibility to Fluconazole in Clinical Isolates of Candida spp. in Both Planktonic and Biofilm Form. Microorganisms 2024; 12:153. [PMID: 38257980 PMCID: PMC10820201 DOI: 10.3390/microorganisms12010153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2023] [Revised: 01/05/2024] [Accepted: 01/10/2024] [Indexed: 01/24/2024] Open
Abstract
Candida spp. are an important opportunistic pathogen that can represent a possible cause of severe infections, especially in immunocompromised individuals. The clinical impact of Candida spp. depends, in part, on the ability to form biofilms, communities of nestled cells into the extracellular matrix. In this study, we compared the biofilm formation ability of 83 strains of Candida spp. isolated from blood cultures and other materials, such as respiratory samples, urine, and exudate, and their sensitivity to fluconazole (FLZ). Strains were divided into tertiles to establish cut-offs to classify isolates as low, moderate, or high biofilm producers (<0.26, 0.266-0.839, >0.839) and biofilms with low, moderate, or high metabolic activity (<0.053, 0.053-0.183, >0.183). A non-linear relationship between biofilm production and metabolic activity was found in C. glabrata and C. tropicalis. In addition, the increase in minimum biofilm eradication concentrations (MBEC50) compared to the Minor Inhibitory Concentration (PMIC) of the planktonic form in Candida spp. confirms the role of biofilm in the induction of resistance to FLZ.
Collapse
Affiliation(s)
- Anna Marzucco
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
- Department of Medical and Surgical Sciences—DIMEC, Alma Mater Studiorum—University of Bologna, 40126 Bologna, Italy; (C.C.); (M.B.); (A.M.D.P.)
| | - Giulia Gatti
- DIN—Department of Industrial Engineering, Alma Mater Studiorum—University of Bologna, 40126 Bologna, Italy;
| | - Maria Sofia Montanari
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Michela Fantini
- Health Services Research, Evaluation and Policy Unit, AUSL Romagna, 42123 Rimini, Italy;
| | - Claudia Colosimo
- Department of Medical and Surgical Sciences—DIMEC, Alma Mater Studiorum—University of Bologna, 40126 Bologna, Italy; (C.C.); (M.B.); (A.M.D.P.)
| | - Maria Vittoria Tamburini
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Valentina Arfilli
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Manuela Morotti
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Pasqualina Schiavone
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Francesco Congestrì
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Martina Manera
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Agnese Denicolò
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Martina Brandolini
- Department of Medical and Surgical Sciences—DIMEC, Alma Mater Studiorum—University of Bologna, 40126 Bologna, Italy; (C.C.); (M.B.); (A.M.D.P.)
| | - Francesca Taddei
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Laura Grumiro
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Silvia Zannoli
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Giorgio Dirani
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
| | - Alessandra Mistral De Pascali
- Department of Medical and Surgical Sciences—DIMEC, Alma Mater Studiorum—University of Bologna, 40126 Bologna, Italy; (C.C.); (M.B.); (A.M.D.P.)
| | - Vittorio Sambri
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
- Department of Medical and Surgical Sciences—DIMEC, Alma Mater Studiorum—University of Bologna, 40126 Bologna, Italy; (C.C.); (M.B.); (A.M.D.P.)
| | - Monica Cricca
- Unit of Microbiology, The Great Romagna Hub Laboratory, 47522 Pievesestina, Italy; (M.S.M.); (M.V.T.); (V.A.); (M.M.); (P.S.); (F.C.); (M.M.); (A.D.); (F.T.); (L.G.); (S.Z.); (G.D.); (V.S.); (M.C.)
- Department of Medical and Surgical Sciences—DIMEC, Alma Mater Studiorum—University of Bologna, 40126 Bologna, Italy; (C.C.); (M.B.); (A.M.D.P.)
| |
Collapse
|
2
|
Loparco D, Orlando L, Caloro M, Caliolo C, Quaranta A, Schiavone P, Fedele P, Rendini M, Varriano R, Morleo A, Falcone L, Lotti G, Cinefra M, Ferrara P, Rizzo P, Marino A, Calvani N, Mazzoni E, D’Amico M, Cinieri S. Final results of scalp cooling for hair preservation: A single- institution prospective study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz240.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Loparco D, Orlando L, Caloro M, Chiara C, Quaranta A, Schiavone P, Fedele P, Rendini M, Bonuso V, Cinieri S. Final results of scalp cooling for hair preservation: A single-institution prospective study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz096.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Loparco D, Orlando L, Caloro M, Fedele P, Schiavone P, Quaranta A, Caliolo C, Cinefra M, Ferrara P, Falcone L, Capone V, Destro C, Morleo A, Ricco A, Bonuso V, Lotti G, D'amico M, Rizzo P, Marino A, Cinieri S. Bald is beautiful: No more. The stigma of alopecia during chemotherapy: Brindisi oncology department experience. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy300.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Torri A, Bertini S, Schiavone P, Congestrì F, Matteucci M, Sparacino M, Testa G, Pedna MF, Sambri V. Shewanella algae infection in Italy: report of 3 years' evaluation along the coast of the northern Adriatic Sea. New Microbes New Infect 2018; 23:39-43. [PMID: 29556408 PMCID: PMC5854895 DOI: 10.1016/j.nmni.2018.01.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 12/29/2017] [Accepted: 01/04/2018] [Indexed: 11/02/2022] Open
Abstract
Shewanella algae are Gram-negative, nonfermentative, motile bacilli, classified in the genus Shewanella in 1985. These environmental bacteria are occasionally identified in human infections, with a relatively strong association with exposure to seawater during warm seasons. This report describes a case series of 17 patients with infection correlated to S. algae in the coastal area of Romagna, Italy, from 2013 to 2016. The types of infection included otitis, pneumonia, sepsis and soft tissue (wound). Exposure to the marine environment during hot months was confirmed in 12 of 17 patients. An apparent correlation between increased severity of infection and patient age was also observed.
Collapse
Affiliation(s)
- A Torri
- Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina (FC), Italy
| | - S Bertini
- Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina (FC), Italy
| | - P Schiavone
- Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina (FC), Italy
| | - F Congestrì
- Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina (FC), Italy
| | - M Matteucci
- Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina (FC), Italy
| | - M Sparacino
- Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina (FC), Italy
| | - G Testa
- Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina (FC), Italy
| | - M F Pedna
- Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina (FC), Italy
| | - V Sambri
- Unit of Microbiology, The Great Romagna Hub Laboratory, Pievesestina (FC), Italy.,DIMES, University of Bologna, Bologna, Italy
| |
Collapse
|
6
|
Orlando L, Caloro M, Lutrino E, Loparco D, Caliolo C, Schiavone P, Quaranta A, Fedele P, Rizzo P, D'Amico M, Chetrì M, Marino A, Mazzoni E, Calvani N, Nacci A, Sponziello F, Cinefra M, Ferrara P, Falcone L, Cinieri S. We are all Jews of somebody: migration and genetic. The story of Jewish settlements in Italian Salento. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
Loparco D, Caloro M, Orlando L, Lutrino E, Schiavone P, Caliolo C, Quaranta A, Fedele P, Mazzoni E, Calvani N, Cinefra M, Ferrara P, Falcone L, Lanzilotti A, Capone V, Cristina D, Lotti G, Ricco A, Morleo A, Cinieri S. Alopecia/hair loss in all patients treated with trastuzumab and paclitaxel: myth or reality? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Caloro M, Orlando L, Lutrino E, Quaranta A, Caliolo C, Schiavone P, Aprile G, Chetrì M, D'Amico M, Rizzo P, Fedele P, Loparco D, Mazzoni E, Marino A, Calvani N, Sponziello F, Nacci A, Cinefra M, Ferrara P, Cinieri S. BRCA1/BRCA2 mutations in a Mediterranean population (Apulia Region) with breast or ovarian cancer: a single center experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Lutrino E, Loparco D, Orlando L, Caloro M, Fedele P, Mazzoni E, Chetrì M, D'Amico M, marino A, Sponziello F, Nacci A, Calvani N, Rizzo P, Caliolo C, Quaranta A, Schiavone P, Cinefra M, Ferrara P, Lanzilotti A, Cinieri S. Bald is beautiful: no more. The stigma of alopecia during chemotherapy: Brindisi Oncology Department experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Lutrino E, Orlando L, Giordano G, Zamagni C, Caliolo C, Febbraro A, Giampaglia M, Dima G, Quaranta A, Scavelli C, Bilancia D, Filippelli G, Fontanella C, Schiavone P, Fedele P, Enrica M, Rubino D, Cinieri S. Safety and efficacy of eribulin plus trastuzumab in pretreated HER2-positive advanced breast cancer (ABC) patients. An Italian multicenter experience. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.26] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Orlando L, Lutrino E, Giordano G, Zamagni C, Caliolo C, Febbraro A, Giampaglia M, Dima G, Rubino D, Scavelli C, Schiavone P, Bilancia D, Filippelli G, Quaranta A, Fedele P, Mazzoni E, Fontanella C, Cinieri S. Safety of Eribulin plus Trastuzumab in pre-treated HER2-positive advanced breast cancer (ABC) patients: results from an Italian observational study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw337.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Marini M, Musiani D, Raggi MA, Schiavone P, Levine RL. Oxidative stress does not mediate heat shock-induced cell damage and apoptosis. Redox Rep 2016; 3:57-63. [DOI: 10.1080/13510002.1997.11747091] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
13
|
Orlando L, Lutrino E, Fedele P, Quaranta A, Caliolo C, Schiavone P, Fontanella C, Nacci A, Calvani N, D'Amico M, Marino A, Mazzoni E, Rizzo P, Sponziello F, Chetrì M, Ferrara P, Cinefra M, Cinieri S. Lapatinib and continuous metronomic capecitabine in HER2 positive advanced breast cancer (ABC): a single center experience. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.46] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
14
|
Lengyel TH, Long R, Schiavone P. Effect of interfacial slippage on the near-tip fields of an interface crack between a soft elastomer and a rigid substrate. Proc Math Phys Eng Sci 2014. [DOI: 10.1098/rspa.2014.0497] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
We consider the role of interfacial slippage in the deformation and stress fields near the tip of a plane interface crack occurring between a compressible hyperelastic material and a rigid substrate. Specifically, we draw comparisons between the two limiting cases of ‘no-slip’ (infinitely high friction) and ‘frictionless’ (zero friction) surfaces by performing corresponding asymptotic analyses in the crack-tip region. Our results indicate that for the no-slip case, when the body is subjected to far-field loading, the crack deforms to a wedge-like shape consistent with experimental observations reported in the literature. Moreover, in this case, the wedge angle is shown to be directly related to ratios of various Cauchy stress components on the bonded surface in the near-tip region. Finite-element simulations reveal that the wedge angle also depends on material compressibility and the far-field loading conditions. By contrast, the analysis of the frictionless case reveals that the crack consistently opens into a smooth parabolic shape with a right wedge angle and near-tip stress field dominated by the normal stress at the surface. The results established here can be used as a basis for the understanding of the role of varying degrees of slippage on interfacial cracks.
Collapse
Affiliation(s)
- T. H. Lengyel
- Department of Mechanical Engineering, University of Alberta, 4-9 Mechanical Engineering Building, Edmonton, Alberta, Canada T6G 2G8
| | - Rong Long
- Department of Mechanical Engineering, University of Alberta, 4-9 Mechanical Engineering Building, Edmonton, Alberta, Canada T6G 2G8
| | - P. Schiavone
- Department of Mechanical Engineering, University of Alberta, 4-9 Mechanical Engineering Building, Edmonton, Alberta, Canada T6G 2G8
| |
Collapse
|
15
|
Ciccarese M, Orlando L, Fedele P, Schiavone P, Maiello E, Cilenti P, Aieta M, Bozza G, Forcignanò M, Febbraro A, Bordonaro R, Romito S, Rinaldi A, Borsellino N, Riccardi F, Pisconti S, Lorusso V, Colucci G, Cinieri S. A Multicenter Phase Ii Trial of Nab-Paclitaxel in Combination with Capecitabine in Patients (Pts) with Her-2 Negative and Triple Negative Advanced Breast Cancer (Abc): an Interim Analysis. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Martini V, Schiavone P, Bonacina R, Mariani U, Rambaldi A. NK leukemia: a rare case of oral manifestations representing the initial sign. Ann Stomatol (Roma) 2013; 4:28. [PMID: 24353795 PMCID: PMC3860219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- V Martini
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - P Schiavone
- Department of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - R Bonacina
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - U Mariani
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - A Rambaldi
- Department of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
17
|
Bonacina R, Martini V, Schiavone P, Mariani U, Rambaldi A. The importance of differential diagnosis between Bronj and hematologic diseases. Ann Stomatol (Roma) 2013; 4:27-28. [PMID: 24353793 PMCID: PMC3860233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- R Bonacina
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - V Martini
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - P Schiavone
- Department of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - U Mariani
- Department of Dentistry, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| | - A Rambaldi
- Department of Hematology, Ospedale Papa Giovanni XXIII, Bergamo, Italy
| |
Collapse
|
18
|
Saglimbene V, D'Alonzo D, Ruospo M, Vecchio M, Natale P, Gargano L, Nicolucci A, Pellegrini F, Craig JC, Triolo G, Procaccini DA, Santoro A, Di Giulio S, La Rosa S, Murgo A, Di Toro Mammarella R, Sambati M, D'Ambrosio N, Greco V, Giannoccaro G, Flammini A, Boccia E, Montalto G, Pagano S, Amarù S, Fici M, Lumaga GB, Mancini E, Veronesi M, Patregnani L, Querques M, Schiavone P, Chimienti S, Palumbo R, Di Franco D, Della Volpe M, Gori E, Salomone M, Iacono A, Moscoloni M, Treglia A, Casu D, Piras AM, Di Silva A, Mandreoli M, Lopez A, Quarello F, Catizone L, Russo G, Forcellini S, Maccarone M, Catucci G, Di Paolo B, Stingone A, D'Angelo B, Guastoni C, Pasquali S, Minoretti C, Bellasi A, Boscutti G, Martone M, David S, Schito F, Urban L, Di Iorio B, Caruso F, Mazzoni A, Musacchio R, Andreoli D, Cossu M, Li Cavoli G, Cornacchiari M, Granata A, Clementi A, Giordano R, Guastoni C, Barzaghi W, Valentini M, Hegbrant J, Tognoni G, Strippoli GFM. [Effects of dose of erythropoiesis stimulating agents on cardiovascular outcomes, quality of life and costs of haemodialysis. the clinical evaluation of the DOSe of erythropoietins (C.E. DOSE) Trial]. G Ital Nefrol 2013; 30:gin/00072.21. [PMID: 23832463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
BACKGROUND Anaemia is a risk factor for death, adverse cardiovascular outcomes and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESA) are the most used treatment option. In observational studies, higher haemoglobin (Hb) levels (around 11-13 g/dL) are associated with improved survival and quality of life compared to Hb levels around 9-10 g/dL. Randomized studies found that targeting higher Hb levels with ESA causes an increased risk of death, mainly due to adverse cardiovascular outcomes. It is possible that this is mediated by ESA dose rather than haemoglobin concentration, although this hypothesis has never been formally tested. METHODS We present the protocol of the Clinical Evaluation of the Dose of Erythropoietins (C.E. DOSE) trial, which will assess the benefits and harms of a high versus a low ESA dose therapeutic strategy for the management of anaemia of end stage kidney disease (ESKD). This is a randomized, prospective open label blinded end-point (PROBE) design trial due to enroll 900 haemodialysis patients. Patients will be randomized 1:1 to 4000 UI/week i. v. versus 18000 UI/week i. v. of epoetin alfa, beta or any other epoetin in equivalent doses. The primary outcome of the trial is a composite of cardiovascular events. In addition, quality of life and costs of these two strategies will be assessed. The study has been approved and funded by the Italian Agency of Drugs (Agenzia Italiana del Farmaco (AIFA)) within the 2006 funding plan for independent research on drugs (registered at www.clinicaltrials.gov (NCT00827021)).
Collapse
|
19
|
Pignanelli S, Zaccherini P, Schiavone P, Nardi Pantoli A, Pirazzoli S, Nannini R. In vitro antimicrobial activity of several antimicrobial agents against Escherichia coli isolated from community-acquired uncomplicated urinary tract infections. Eur Rev Med Pharmacol Sci 2013; 17:206-209. [PMID: 23377809] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
AIM For frequency Escherichia (E.) coli is the agent of urinary tract infections (UTIs). The objective of the present study was to evaluate in vitro activity of several antimicrobial agents to guide empirical treatment of uncomplicated UTIs. In vitro antimicrobial susceptibility of 429 E. coli strains, isolated in urine specimens from community-acquired uncomplicated UTIs in outpatients, was studied during the 1st semester 2011. MATERIALS AND METHODS Urine samples were processed with Robobact/Uriset system. E. coli strains were identified with GN card for VITEK-2 system and API 20E gallery, as confirmatory assay. E. coli strains were tested, for antimicrobial susceptibility, using VITEK-2 system and confirmed with disk diffusion method. RESULTS Penicillins have exhibited sensitivity percentage of 50.9%, inhibitor-protected penicillins 88.9%, cephalosporins 91.6%, carbapenem 100%, aminoglycosides 91.5%, fluoroquinolones 71.8%, nitrofuran 99.3% and sulfonamide 74.1%. CONCLUSIONS In vitro imipenem, nitrofurantoin, cephalosporins and aminoglycosides (>90% of isolates) have the best sensitivity in community-acquired UTIs. In particular nitrofurantoin has showed a low MIC distribution and high sensitivity percentage. Therefore, could be suggested in empirical treatment of these infections.
Collapse
Affiliation(s)
- S Pignanelli
- Department of Diagnostic Services - O.U. Laboratory Analysis of Clinical Chemistry and Microbiology, S. Maria della Scaletta Hospital, Imola, Bologna, Italy.
| | | | | | | | | | | |
Collapse
|
20
|
Fedele P, Nacci A, Lapolla A, Orlando L, Schiavone P, Marino A, Cinefra M, Ardizzone A, De Pasquale M, Cinieri S. Analysis of Correlation Between Weight at Diagnosis, Weight Gain After Breast Cancer Treatment and Recurrence in Women With Early Stage Breast Cancer (EBC). Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)32827-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
21
|
Fedele P, Marino A, Orlando L, Schiavone P, Nacci A, Sponziello F, Rizzo P, Calvani N, Mazzoni E, Cinefra M, Cinieri S. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer 2012; 48:24-9. [DOI: 10.1016/j.ejca.2011.06.040] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2011] [Revised: 06/08/2011] [Accepted: 06/17/2011] [Indexed: 11/25/2022]
|
22
|
Fedele P, Orlando L, Marino A, Mazzoni E, Cinefra M, Nacci A, Sponziello F, Calvani N, Schiavone P, Cinieri S. 5045 POSTER Outcomes of HER2+ Metastatic Breast Cancer (MBC) Patients (PTS) Treated With Continuous Inhibition of HER2 Activity: a Single Institution Study. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71487-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
23
|
Abstract
We consider the effect of surface elasticity on an interface crack between two dissimilar linearly elastic isotropic homogeneous materials undergoing plane deformations. The bi-material is subjected to either remote tension (mode-I) or in-plane shear (mode-II) with the faces of the (interface) crack assumed to be traction-free. We incorporate surface mechanics into the model of deformation by employing a version of the continuum-based surface/interface theory of Gurtin & Murdoch. Using complex variable methods, we obtain a semi-analytical solution valid throughout the entire domain of interest (including at the crack tips) by reducing the problem to a system of coupled Cauchy singular integro-differential equations, which is solved numerically using Chebychev polynomials and a collocation method. It is shown that, among other interesting phenomena, our model predicts finite stress at the (sharp) crack tips and the corresponding stress field to be size-dependent. In particular, we note that, in contrast to the results from linear elastic fracture mechanics, when the bi-material is subjected to uniform far-field stresses (either tension or in-plane shear), the incorporation of surface effects effectively eliminates the oscillatory behaviour of the solution so that the resulting stress fields no longer suffer from oscillatory singularities at the crack tips.
Collapse
Affiliation(s)
- C. I. Kim
- Department of Mechanical Engineering, University of Alberta, Edmonton, Alberta, Canada T6G 2G8
| | - P. Schiavone
- Department of Mechanical Engineering, University of Alberta, Edmonton, Alberta, Canada T6G 2G8
| | - C.-Q. Ru
- Department of Mechanical Engineering, University of Alberta, Edmonton, Alberta, Canada T6G 2G8
| |
Collapse
|
24
|
Fedele P, Orlando L, Schiavone P, Calvani N, Marino A, Nacci A, Sponziello F, Mazzoni E, Rizzo P, Cinieri S. Optimizing outcomes in patients (pts) with HER2+ metastatic breast cancer (MBC) through continuous inhibition of HER2 activity: A single institution study. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e11067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Orlando L, Viale G, Schiavone P, Fedele P, Nacci A, Rizzo P, Calvani N, Sponziello F, Chetri C, Mazzoni E, D' Amico M, Marino A, Cinefra M, Cinieri S. Discordance in pathology report after central pathology review in early breast cancer and its impact on treatment choice. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.585] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Nacci A, Galetta D, Mazzoni E, Rizzo P, Calvani N, Orlando L, Sponziello F, Schiavone P, Fedele P, Chetri C, D' Amico M, Marino A, Cinefra M, Criscuolo M, Cinieri S. Updating data about a first-line modified schedule of gemcitabine with a lower dose than standard in very elderly or PS 2 patients with advanced non-small cell lung cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e18031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Orlando L, Schiavone P, Fedele P, Calvani N, Nacci A, Rizzo P, Marino A, D'Amico M, Sponziello F, Mazzoni E, Cinefra M, Fazio N, Maiello E, Silvestris N, Colucci G, Cinieri S. Molecularly targeted endocrine therapies for breast cancer. Cancer Treat Rev 2011; 36 Suppl 3:S67-71. [PMID: 21129614 DOI: 10.1016/s0305-7372(10)70023-2] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
The identification of the estrogen receptor (ER) provided the first target for antiestrogenic therapeutic agents. Endocrine therapies, either by blocking or downregulating the receptor or by suppressing the estrogen production, inhibit the proliferative effect of estradiol on ER. While the activity on ER is considered a real target-mediated therapy, the effect on enzymatic activity involved in estrogen production (mainly inhibition of aromatase by aromatase inhibitors, AIs, and ovarian ablation) could be considered an "indirect" targeted strategy. In addiction to the direct ligand-ER signal, the complexity of endocrine and non endocrine pathways has led to combination therapies against different targets. Tamoxifen is the widely investigated, most used and representative of drugs blocking the ER and has been introduced in the advanced disease, in neoadjuvant and adjuvant setting and for chemo-prevention of high risk women. Its role has been challenged in the last years by the introduction of third generation aromatase inhibitors that have proven a higher activity than tamoxifen and different toxicity. Several other SERMs (selective estrogen receptor modulators) have been investigated, but none of them was clearly superior to tamoxifen. SERDs (selective estrogen receptor downregulators) act as pure estrogen antagonist. They are used in the treatment of advanced breast cancers and their role in other settings still needs further investigation. Here we discuss the well established data with SERMs, SERDs and AIs, mechanisms underlying resistance and rationale for recycling endocrine compounds and for simultaneously targeting different pathways.
Collapse
Affiliation(s)
- L Orlando
- Medical Oncology Division and Breast Unit, A. Perrino Hospital, Strada Statale 7 (Via Appia), Brindisi, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Pelosi G, Bisceglie F, Bignami F, Ronzi P, Schiavone P, Re MC, Casoli C, Pilotti E. Antiretroviral activity of thiosemicarbazone metal complexes. J Med Chem 2010; 53:8765-9. [PMID: 21121632 DOI: 10.1021/jm1007616] [Citation(s) in RCA: 103] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Thiosemicarbazones display a wide antimicrobial activity by targeting bacteria, fungi, and viruses. Here, we report our studies on the antiviral activity of two thiosemicarbazone metal complexes, [bis(citronellalthiosemicarbazonato)nickel(II)] and [aqua(pyridoxalthiosemicarbazonato)copper(II)] chloride monohydrate, against the retroviruses HIV-1 and HTLV-1/-2. Both compounds exhibit antiviral properties against HIV but not against HTLVs . In particular, the copper complex shows the most potent anti-HIV activity by acting at the post-entry steps of the viral cycle.
Collapse
Affiliation(s)
- Giorgio Pelosi
- Dipartimento di Chimica GIAF, Università di Parma, Viale G.P. Usberti 17A, 43124 Parma, Italy
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Rizzo P, Nacci A, Mazzoni E, Orlando L, Sponziello F, Calvani N, Schiavone P, D'Amico M, Marino A, Fedele P, Chetri M, Cinefra M, Cinieri S. 72 KAPOSI'S SARCOMA TREATED CONTINUOUSLY FOR ABOUT THREE YEARS WITH WEEKLY AND BI-WEEKLY VINBLASTINE WITH GOOD DISEASE CONTROL: A CASE REPORT. Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70098-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Calvani N, Chetri M, Cinefra M, D'Amico M, Fedele P, Marino M, Mazzoni E, Nacci A, Orlando L, Rizzo P, Schiavone P, Sponziello F, Cinieri S. 15 A RETROSPECTIVE ANALYSIS OF CONTINUING ANDROGEN DEPRIVATION IN HORMONE-REFRACTORY PROSTATE CANCER. Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70041-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
31
|
Fedele P, Orlando L, Schiavone P, Rizzo P, Calvani N, Marino A, D'Amico M, Sponziello F, Nacci A, Mazzoni E, Chetri' M, Cinefra M, Cinieri S. 18 SAFETY AND EFFICACY OF LOW DOSE METRONOMIC CHEMOTHERAPY WITH CAPECITABINE IN HEAVILY PRETREATED METASTATIC BREAST CANCER (MBC) PATIENTS. Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70044-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
32
|
Mazzoni E, Nacci A, Rizzo P, Orlando L, Sponziello F, Calvani N, Schiavone P, D'Amico M, Marino A, Fedele P, Chetri M, Cinefra M, Cinieri S. 52 THIRD LINE TREATMENT WITH A MODIFIED SCHEDULE OF VINORELBINE IN ADVANCED NSCLC PATIENTS WITH A POOR ECOG PERFORMANCE STATUS. Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70078-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
33
|
Turaccio M, Nacci A, Sponziello F, Calvani N, Chetri M, Cinefra M, D'Amico M, Fedele P, Marino A, Mazzoni E, Orlando L, Rizzo P, Schiavone P, Cinieri S. 65 PROGETTO A.M.O.R.E. – Assistenza Mirata Oncologica alla peRsona in trattamEnto. Cancer Treat Rev 2010. [DOI: 10.1016/s0305-7372(10)70091-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
34
|
Orlando L, Fedele P, Schiavone P, Mazzoni E, Cinefra M, D'amico M, Burlizzi S, Portaluri M, Criscuolo M, Cinieri S. New combinations of anthracyclines, cisplatin, and metronomic capecitabine as preoperative chemotherapy for operable and locally advanced breast cancer: First data of efficacy and tolerability. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e11017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
35
|
Nacci A, Maiello E, Mazzoni E, Calvani N, Orlando L, Sponziello F, Schiavone P, Rizzo P, Fedele P, Cinieri S. Effect of first-line modified schedule of gemcitabine on clinical benefit rate and toxicity in elderly or PS 2 patients with advanced non-small cell lung cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e18131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Fedele P, Orlando L, Schiavone P, Rizzo P, Calvani N, D'Amico M, Marino A, Sponziello F, Nacci e S. Cinieri A. Safety and efficacy of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
37
|
Re MC, Vitone F, Biagetti C, Schiavone P, Alessandrini F, Bon I, de Crignis E, Gibellini D. HIV-1 DNA proviral load in treated and untreated HIV-1 seropositive patients. Clin Microbiol Infect 2009; 16:640-6. [PMID: 19732081 DOI: 10.1111/j.1469-0691.2009.02826.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
As proviral human immunodeficiency virus type 1 (HIV-1) DNA can replenish and revive viral infection upon activation, its detection might offer significant therapeutic information, complementing the input provided by plasma RNA determination in the follow-up of infected individuals. A selected group of acutely infected subjects was studied to verify both total and 2-long terminal repeat (2-LTR) DNA proviral load during the acute phase of infection and thereafter. Patients were divided in two sex- and age-matched groups: 19 naive individuals who did not receive antiretroviral therapy during the observation period and 20 subjects treated according to current guidelines. Total and 2-LTR HIV-1 DNA proviral load, in addition to RNA viral load and CD4 cell count, were determined in peripheral blood mononuclear cells (PBMC) at baseline, 6 and 12 months after the first sampling. Total and 2-LTR HIV-1 DNA proviral load exhibited no significant variation at any time in the naive patients (total HIV-1 DNA ranging from 896 + or - 731 to 715 + or - 673 copies/10(5) PBMC and 2-LTR HIV-1 DNA ranging from 94 + or - 105 to 65 + or - 44 copies/10(5) PBMC), whereas a significant reduction in both total HIV-1 DNA (ranging from 997 + or - 676 to 262 + or - 174 copies/10(5) PBMC) and 2-LTR HIV-1 DNA proviral load (ranging from 116 + or - 55 to 26 + or - 35 copies/10(5) PBMC) was detected in highly active antiretroviral therapy (HAART) patients, together with a CD4(+) T cell count increase and RNA load decrease. HAART negatively affects both the labile HIV burden and the integrated proviral DNA, at least in the initial period of successful treatment, suggesting that quantification of HIV-1 DNA proviral load may be an important parameter in monitoring HIV infection.
Collapse
Affiliation(s)
- M C Re
- Department of Haematology and Oncologic Science, Microbiology Section, National Institute Biostructure and Biosystem (INBB), Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Orlando L, Fedele P, Cinefra M, Sponziello F, Calvani N, Chetrì MC, Rizzo P, D'Amico M, Schiavone P, Portaluri M, Criscuolo M, Burlizzi S, Cinieri S. Adjuvant endocrine treatment in premenopausal early breast cancer. Oncology 2009; 77 Suppl 1:9-13. [PMID: 20130426 DOI: 10.1159/000258490] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
The impact of endocrine therapies in the adjuvant treatment of premenopausal patients with early breast cancer is well established. However, the right combination and duration of endocrine manipulations currently available (luteinizing hormone-releasing hormone analogs and tamoxifen) remain unclear. Moreover, the role of chemotherapy in addition to endocrine therapies is not clearly defined. The most recent Early Breast Cancer Trialists' Collaborative Group overview has confirmed the efficacy of five years of tamoxifen in reducing the annual recurrence rate and the annual breast cancer death rate by 41 and 34%, respectively, in an estrogen receptor-positive population. These results are largely irrespective of age, use of chemotherapy or other tumor features. Moreover, the expert panel of the St. Gallen Conference accepted both tamoxifen or tamoxifen plus ovarian suppression as standard endocrine therapy for premenopausal breast cancer patients with endocrine-responsive disease. The use of ovarian suppression or ablation also significantly reduced the risk of breast cancer-related death, mainly in the absence of other systemic therapies. Chemotherapy is widely used in this population; however, its role in endocrine-positive premenopausal women with hormone-positive disease treated with optimal endocrine therapy remains unclear.
Collapse
Affiliation(s)
- L Orlando
- Breast Unit, Medical Oncology Division, Ospedale Senatore A. Perrino, Brindisi, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Schiavone P, Boudou T, Promayon E, Perrier P, Payan Y. A light sterilizable pipette device for the in vivo estimation of human soft tissues constitutive laws. Annu Int Conf IEEE Eng Med Biol Soc 2008; 2008:4298-4301. [PMID: 19163663 DOI: 10.1109/iembs.2008.4650160] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
This paper introduces a new light device for the in vivo estimation of human soft tissues constitutive laws. It consists of an aspiration pipette able to meet the very severe sterilization and handling issues imposed during surgery. The simplicity of the device, free of any electronic circuitry, allows using it as an ancillary instrument. The deformation of the aspired tissue is imaged via a mirror using an external camera. The paper describes the experimental setup as well as the protocol that should be used during surgery. First feasibility measurements are shown for human tongue and forearm skin.
Collapse
Affiliation(s)
- P Schiavone
- TIMC-IMAG Laboratory, UMR UJF CNRS, 5525, Faculté de Médecine de Grenoble, Pavillon Taillefer, F38706 La Tronche Cédex, France
| | | | | | | | | |
Collapse
|
40
|
Schiavone P, Boudou T, Ohayon J, Payan Y. In vivomeasurement of the human soft tissues constitutive laws. Applications to computer aided surgery. Comput Methods Biomech Biomed Engin 2007. [DOI: 10.1080/10255840701479982] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
41
|
Alessandrini F, Bon I, Gorini G, Schiavone P, Vitone F. MUTAZIONI ASSOCIATE A FARMACORESISTENZA NEL PLASMA E NEI LINFOCITI DI SOGGETTI HIV-1 SIEROPOSITIVI. Microbiol Med 2006. [DOI: 10.4081/mm.2006.3349] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
42
|
Prencipe M, Angelini P, D'Amelio A, Mancini A, Schiavone P. [Ultrasound investigation in Apulo-Lucano renal echography study group of the Italian Society of Nephrology: a cognitive report]. G Ital Nefrol 2006; 23:502-7. [PMID: 17123263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
The number of ultrasonography expert consultant Nephrologists is more and more increasing thanks to the contribution that this methodology has brought in both clinical and treatment fields. Up to now, a database of the ultrasonography benefits, as well as the main criteria for the interpretation of the urinary tract echographic examination has not been compiled, yet. We have therefore drawn up and distributed a questionnaire to the consultant nephrologists of the urinary tract echography study group (Apulo-Lucano division). This questionnaire is made up of 27 ultrasonography application and interpretation issues; it aims mainly at creating a common 'language' to reduce the variety of 'descriptors' currently employed by all different specialists and centres involved. 60 consultant nephrologists participated in the study, from the 29 Nephrology and Dialysis O.U.s of Puglia and Basilicata regions, where there is an active echographic service. Data collected show the key role of ultrasonography investigation for all nephrology patients, as high quality and cost efficient test procedure. Moreover, despite the fact that there are differences in echographic examination performance and interpretation, literature data show clearly that it is fundamental to follow general shared principles. The responsibility and task of those specializing in this discipline should be to allow reproduction and comparison of ultrasonographies, also among different operators and centres, and meta studies, i.e. 'a series of comparative studies', which are still very few in number.
Collapse
Affiliation(s)
- M Prencipe
- U.O. Nefrologia e Dialisi, Ospedale 'Casa Sollievo della Sofferenza', IRCCS, S.G. Rotondo (FG) - Italy
| | | | | | | | | |
Collapse
|
43
|
Vitone F, Gibellini D, Schiavone P, Bon I, Re M. LA DETERMINAZIONE QUANTITATIVA DI HIV-1 DNA NEL FOLLOW-UP DEL PAZIENTE HIV-1 INFETTO. Microbiol Med 2005. [DOI: 10.4081/mm.2005.3564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
44
|
Re MC, Bon I, Schiavone P, Vitone F, Gibellini D. Discordant resistance interpretations in multi-treated HIV-1 patients. Int J Antimicrob Agents 2005; 25:211-5. [PMID: 15737514 DOI: 10.1016/j.ijantimicag.2004.10.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2004] [Accepted: 10/06/2004] [Indexed: 11/23/2022]
Abstract
The routine determination of drug resistance has become an important part of the clinical management of HIV-1 infected patients. Plasma samples from 130 individuals treated for at least 1 year with multiple NRTIs and NNRTIs were tested for the presence of mutations correlated to drug resistance. Since interpretation criteria represent a crucial point for virologists and clinicians, often complicated by the presence of novel and/or complex mutations patterns, we analyzed results interpreted by TruGene HIV-1 (Visible Genetics, Toronto, Ontario, Canada) and VirtualPhenotype (Virco, Mechelen, Belgium). A high degree of concordance was found for NNRTIs whereas NRTIs interpretation was highly discrepant. Since different approaches to monitoring resistance reflect different interpretation of results, the prediction of drugs resistance from a given HIV sequence might be contradictory and requires accurate standardization and unique interpretative rules.
Collapse
Affiliation(s)
- M C Re
- Department of Clinical and Experimental Medicine, Section of Microbiology, University of Bologna, St. Orsola Hospital, Massarenti, 9, 40138 Bologna, Italy.
| | | | | | | | | |
Collapse
|
45
|
Re MC, Bon I, Monari P, Borderi M, Gibellini D, Schiavone P, Vitone F, Chiodo F, La Placa M. Mutation patterns of the reverse transcriptase genes in HIV-1 infected patients receiving combinations of nucleoside and non nucleoside inhibitors. Int J Antimicrob Agents 2003; 22:388-94. [PMID: 14522102 DOI: 10.1016/s0924-8579(03)00082-7] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
A genotyping assay was used to define human immunodeficiency virus type 1 (HIV-1) reverse transcriptase codons in plasma samples from 80 HIV-1 patients extensively treated with two nucleoside reverse transcriptase (zidovudine and lamivudine) and one non nucleoside reverse transcriptase (nevirapine) inhibitor. The frequencies of T215S/Y/F, M41L, D67N, L210W K70R, K219Q mutations, detectable in plasma samples, conferring resistance to zidovudine were 61.2, 56.2, 36.2, 31.5, 27.5 and 17.5%, respectively. Mutations (M184V or M184I) conferring resistance to lamivudine were detected in an extremely high percentage of patients (61%). Among mutations correlated to high (K103N, V106A, Y181C/I, Y188C/H/L, G190A/C/E/Q/S/T) or moderate (V108I, V118I) levels of nevirapine resistance, the predominant amino acid change was a substitution at 103 codon, present in 24 of 80 samples tested. Finally Q151M, the marker mutation able to confer resistance to all nucleoside analogues, was detected in seven patients with a viral load of between 1 x 10(4) and 9 x 10(4) HIV-1 RNA copies/ml. The relationship between the genotype and the viral load showed that the incidence of some specific mutations [M41L, T215Y (correlated to zidovudine resistance) and K103N (correlated to all NNRTIs drugs)] significantly (P=0.001) increased with higher viral load. Our results, albeit limited to a small cohort, showed a high frequency of mutations correlated to drugs in use, suggesting a need for therapeutic change in the near future and demonstrating that the development of genotyping tests helps to guide the therapeutic management of HIV-1 infected people. Our data highlight the dangers of selecting antiretroviral therapy without previous antiretroviral drug testing. Although the cost of these assays is a concern, prescribing inefficacious drugs could create serious problems for HIV-1 patients.
Collapse
Affiliation(s)
- Maria Carla Re
- Section of Microbiology, Department of Clinical and Experimental Medicine, University of Bologna, St. Orsola Hospital, Via Massarenti 9, 40138 Bologna, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Re MC, Bon I, Monari P, Gorini R, Schiavone P, Gibellini D, La Placa M. Drug failure during HIV-1 treatment. New perspectives in monitoring drug resistance. New Microbiol 2003; 26:405-13. [PMID: 14596353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
Since the discovery of 3'-azido-3'deoxthymidine (zidovudine) as an effective antiretroviral agent against human immunodeficiency virus type 1 (HIV-1), drug therapy has been widely used in the treatment of AIDS. To date, new combination therapies have significantly altered the longterm prognosis for HIV-infected patients showing a reduction of plasma viral load, associated with clinical and immunological recovery. Nevertheless, in various circumstances treatment can fail for several reasons, such as patient noncompliance with the therapeutic regimen, suboptimal antiviral drug concentrations, drug pharmacokinetics, and virus resistance to one or more drugs. Virus drug resistance is the most important factor contributing to the failure of antiretroviral therapy. Since some evidence indicates that viral resistance and treatment failure are closely linked, this brief review explores the routine determination of drug resistance and its importance to shed more light on the meaning of mutations correlated to drug resistance.
Collapse
Affiliation(s)
- M C Re
- Department of Clinical and Experimental Medicine, Section of Microbiology, University of Bologna, Via Massarenti, 9, 40138, Bologna, Italy.
| | | | | | | | | | | | | |
Collapse
|
47
|
Re MC, Monari P, Bon I, Borderi M, Gibellini D, Schiavone P, Vitone F, Furlini G, La Placa M. Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz. Int J Antimicrob Agents 2002; 20:223-6. [PMID: 12385703 DOI: 10.1016/s0924-8579(02)00164-4] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
The study evaluated the development of drug resistance in a group of HIV-1 patients. After failure to respond to previous therapy with two non-nucleoside reverse transcriptase inhibitors (NNRTIs), as assessed by the presence of a rebound in viral load or a constant high level of HIV plasma viraemia, the patients were treated with a combination of stavudine, lamivudine and efavirenz (EFV). Results showed that viruses carrying primary mutations, usually K103N, T215Y and M41L, presented higher levels of HIV-1 RNA, suggesting an association between a precise mutation pattern and treatment failure.
Collapse
Affiliation(s)
- M C Re
- Section of Microbiology, Department of Clinical and Experimental Medicine, St Orsola Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Morrone LF, Ettorre GC, Passavanti G, Tampoia M, Schiavone P, Coratelli P. Maxillary brown tumor in secondary hyperparathyroidism requiring urgent parathyroidectomy. J Nephrol 2001; 14:415-9. [PMID: 11730277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/22/2023]
Abstract
Brown tumors are unusual but serious complications of renal osteodystrophy, and can be successfully treated by parathyroidectomy or by pharmacological treatment of hyperparathyroidism. Brown tumors in patients with severe hyperparathyroidism (HPT) secondary to renal failure have been increasingly reported. We describe an unusual case of brown tumors at the maxillary bone and the seventh right rib, in a 57-year old man with a long history of hemodialysis. The maxillary lesion caused serious local discomfort due to its rapid growth. In this setting, surgical total parathyroidectomy was chosen as the most adequate therapeutic approach, given the previous unsatisfactory response to calcitriol. After successful parathyroidectomy, rapid healing was achieved with sclerosis of both brown tumors, as documented by serial computerized tomograms. In conclusion, although vitamin D therapy has been beneficial in several cases of secondary hyperparathyroidism complicated by brown tumors, we propose that whenever regression of the tumor bulk is urgently needed, as in our case, parathyroidectomy should be the first treatment choice.
Collapse
Affiliation(s)
- L F Morrone
- Department of Internal Medicine and Public Medicine, University of Bari, Polyclinic, Italy.
| | | | | | | | | | | |
Collapse
|
49
|
Affiliation(s)
- P. Schiavone
- Department of Mechanical Engineering, University of Alberta, Edmonton, Alberta, Canada T6G 2G8
| | - C. Q. Ru
- Department of Mechanical Engineering, University of Alberta, Edmonton, Alberta, Canada T6G 2G8
| |
Collapse
|
50
|
Raggi MA, Schiavone P, Mandrioli R, Bugamelli F, Frabetti F, Marini M. Spectrophotometric determination of thiols in human lymphocytes. Pharmazie 1998; 53:239-42. [PMID: 9583085] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
A spectroscopic method for thiol analysis, based on the complexation reaction with Pd(II), is described. The proposed method is simple and sensitive and can be used for a rapid analysis of thiols in human lymphocytes.
Collapse
Affiliation(s)
- M A Raggi
- Dipartimento di Scienze Farmaceutiche, Università di Bologna, Italy
| | | | | | | | | | | |
Collapse
|